Patents by Inventor Young-Jun Shin

Young-Jun Shin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIPERIDINEDIONE DERIVATIVES
    Publication number: 20260035354
    Abstract: The present invention relates to a PROTAC compound which can increase the degradation effect of a protein of interest, and to a novel piperidinedione compound which can be used as an E3 enzyme ligand of the PROTAC compound. The piperazinedione derivative compound of the present invention acts on CRBN and thus may be used as a therapeutic agent (for example, an anticancer agent or an immunomodulator) for diseases associated with CRBN proteins.
    Type: Application
    Filed: June 25, 2025
    Publication date: February 5, 2026
    Applicant: INNOCURE THERAPEUTICS, INC.
    Inventors: Hye-Dong YOO, Young-Jun SHIN, Sung Jin KIM
  • Piperidinedione derivatives
    Patent number: 12384756
    Abstract: Disclosed is a novel piperidinedione compound of Formula 1 or a pharmaceutically acceptable salt thereof. Uses of the novel piperidinedione compound of Formula 1 or a pharmaceutically acceptable salt thereof as an anti-tumor agent or an immunomodulatory for treatment of CRBN protein-mediated diseases are disclosed. Also the compound or salt thereof can be used an E3 ligase binder in a PROTAC compound comprising a protein of interest ligand, a linker and an E3 ligase binder.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: August 12, 2025
    Assignee: INNOCURE THERAPEUTICS, INC.
    Inventors: Hye-Dong Yoo, Young-Jun Shin, Sung Jin Kim, Bo Kyoung Kim, Eun Myong Lee, So Hyun Shin, Yong Hwan Kim, Seo Won Choi, Min Sik Bae, Dongsik Yang, Jeong Hyun Hong, Jin Keon Pai
  • MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    Publication number: 20250009693
    Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Application
    Filed: February 14, 2024
    Publication date: January 9, 2025
    Inventors: Thuy-Anh TRAN, Weichao CHEN, Bryan A. KRAMER, Abu J.M. SADEQUE, Anna SHIFRINA, Young-Jun SHIN, Pureza VALLAR, Ning ZOU
  • Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto
    Patent number: 11987588
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure and related disorders thereto.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: May 21, 2024
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Thuy-Anh Tran, Brett Ullman, Bryan Aubrey Kramer, Quyen-Quyen Thuy Do, Young-Jun Shin
  • MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    Publication number: 20230404954
    Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Application
    Filed: April 28, 2023
    Publication date: December 21, 2023
    Inventors: Thuy-Anh TRAN, Weichao CHEN, Bryan A. KRAMER, Abu J.M. SADEQUE, Anna SHIFRINA, Young-Jun SHIN, Pureza VALLAR, Ning ZOU
  • PIPERIDINEDIONE DERIVATIVES
    Publication number: 20230295105
    Abstract: Disclosed is a novel piperidinedione compound of Formula 1 or a pharmaceutically acceptable salt thereof. Uses of the novel piperidinedione compound of Formula 1 or a pharmaceutically acceptable salt thereof as an anti-tumor agent or an immunomodulatory for treatment of CRBN protein-mediated diseases are disclosed. Also the compound or salt thereof can be used an E3 ligase binder in a PROTAC compound comprising a protein of interest ligand, a linker and an E3 ligase binder.
    Type: Application
    Filed: November 15, 2021
    Publication date: September 21, 2023
    Applicant: INNOCURE THERAPEUTICS, INC.
    Inventors: Hye-Dong YOO, Young-jun SHIN, Sung Jin KIM, Bo Kyoung KIM, Eun Myong LEE, So Hyun SHIN, Yong Hwan KIM, Seo Won CHOI, Min Sik BAE, Dongsik YANG, Jeong Hyun HONG, Jin Keon PAI
  • MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    Publication number: 20230121825
    Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Application
    Filed: June 7, 2022
    Publication date: April 20, 2023
    Inventors: Thuy-Anh TRAN, Weichao CHEN, Bryan A. KRAMER, Abu J.M. SADEQUE, Anna SHIFRINA, Young-Jun SHIN, Pureza VALLAR, Ning ZOU
  • MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO
    Publication number: 20220396579
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor.
    Type: Application
    Filed: April 22, 2022
    Publication date: December 15, 2022
    Inventors: Thuy-Anh Tran, Brett Ullman, Bryan Aubrey Kramer, Quyen-Quyen Thuy Do, Young-Jun Shin
  • HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION
    Publication number: 20220281825
    Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Application
    Filed: April 21, 2022
    Publication date: September 8, 2022
    Applicant: Arisan Therapeutics Inc.
    Inventors: Kenneth McCormack, Michael Bruno Plewe, Nadezda Sokolova, Gregory Henkel, Eric Brown, Vidyasagar Reddy Gantla, Young-Jun Shin
  • Heterocyclic compounds for the treatment of arenavirus
    Patent number: 11352328
    Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: June 7, 2022
    Assignee: Arisan Therapeutics Inc.
    Inventors: Michael Plewe, Eric Brown, Vidyasagar Gantla, Gregory Henkel, Kenneth McCormack, Nadzeda V. Sokolova, Young-Jun Shin
  • Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto
    Patent number: 11339172
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure and related disorders thereto.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 24, 2022
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Thuy-Anh Tran, Brett Ullman, Bryan Aubrey Kramer, Quyen-Quyen Thuy Do, Young-Jun Shin
  • Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
    Patent number: 11098034
    Abstract: Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: August 24, 2021
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Thuy-Anh Tran, Jason B. Ibarra, Young-Jun Shin, Brett Ullman, Ning Zou, Xi Zeng
  • PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    Publication number: 20200392123
    Abstract: Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Application
    Filed: April 30, 2020
    Publication date: December 17, 2020
    Inventors: Thuy-Anh TRAN, Jason B. IBARRA, Young-Jun SHIN, Brett ULLMAN, Ning ZOU, Xi ZENG
  • MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO
    Publication number: 20200385395
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor.
    Type: Application
    Filed: December 6, 2018
    Publication date: December 10, 2020
    Inventors: Thuy-Anh Tran, Brett Ullman, Bryan Aubrey Kramer, Quyen-Quyen Thuy Do, Young-Jun Shin
  • MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    Publication number: 20200375930
    Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Application
    Filed: April 14, 2020
    Publication date: December 3, 2020
    Inventors: Thuy-Anh TRAN, Weichao CHEN, Bryan A. KRAMER, Abu J.M. SADEQUE, Anna SHIFRINA, Young-Jun SHIN, Pureza VALLAR, Ning ZOU
  • Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
    Patent number: 10689372
    Abstract: Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 23, 2020
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Thuy-Anh Tran, Jason B. Ibarra, Young-Jun Shin, Brett Ullman, Ning Zou, Xi Zeng
  • Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
    Patent number: 10668033
    Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: June 2, 2020
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Thuy-Anh Tran, Weichao Chen, Bryan A. Kramer, Abu J. M. Sadeque, Anna Shifrina, Young-Jun Shin, Pureza Vallar, Ning Zou
  • Heterocyclic Compounds for the Treatment of Arenavirus
    Publication number: 20190308938
    Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Application
    Filed: July 7, 2017
    Publication date: October 10, 2019
    Inventors: Kenneth McCormack, Michael Bruno Plewe, Nadezda Sokolova, Gregory Henkel, Eric Brown, Vidyasagar Reddy Gantla, Young-Jun Shin
  • PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    Publication number: 20190270731
    Abstract: Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Application
    Filed: November 6, 2018
    Publication date: September 5, 2019
    Inventors: Thuy-Anh Tran, Jason B. Ibarra, Young-Jun Shin, Brett Ullman, Ning Zou, Xi Zeng
  • Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
    Patent number: RE50267
    Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Grant
    Filed: May 18, 2022
    Date of Patent: January 14, 2025
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Thuy-Anh Tran, Weichao Chen, Bryan A. Kramer, Abu J. M. Sadeque, Anna Shifrina, Young-Jun Shin, Pureza Vallar, Ning Zou